Physician profile
Daniel St Amour
NPI 1164933354
$2,293.64
in general payments reported to CMS, 2019-2025
9 companies · $666 in 2025
The $666 reported for 2025 was more than what 78% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $230 · 2023: $805 · 2024: $476 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,945.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,348.17 | 2021-2025 | |
| Alkermes, INC. | $287.15 | 2021-2025 | Aristada, Vivitrol, Lybalvi |
| Vanda Pharmaceuticals INC. | $263.91 | 2024-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $195.91 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Indivior INC. | $85.98 | 2023-2024 | Sublocade |
| Braeburn INC. | $48.46 | 2023-2025 | Brixadi |
| Lundbeck LLC | $22.67 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $21.28 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.11 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel St Amour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.